Clinical Trial Update: AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV [Phase 2]

View source ↗

Summary

Phase 2 trial update for AVX754, a new nucleoside reverse transcriptase inhibitor, in drug-resistant HIV; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• AVX754 (AVX754)

Snippet

Sponsor: Avexa | Conditions: HIV Infections | Phase 2 | Status: COMPLETED